CY1106558T1 - Glp-2 σκευασματα - Google Patents

Glp-2 σκευασματα

Info

Publication number
CY1106558T1
CY1106558T1 CY20071100588T CY071100588T CY1106558T1 CY 1106558 T1 CY1106558 T1 CY 1106558T1 CY 20071100588 T CY20071100588 T CY 20071100588T CY 071100588 T CY071100588 T CY 071100588T CY 1106558 T1 CY1106558 T1 CY 1106558T1
Authority
CY
Cyprus
Prior art keywords
glp
formulations
histidine
analogs
mannitol
Prior art date
Application number
CY20071100588T
Other languages
English (en)
Inventor
Indu J. Isaacs
Original Assignee
Nps Allelix Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10867197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106558(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nps Allelix Corporation filed Critical Nps Allelix Corporation
Publication of CY1106558T1 publication Critical patent/CY1106558T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Η εφεύρεση εστιάζεται σε σκευάσματα GLP-2 πεπτιδίων και αναλόγων αυτών τα οποία εμφανίζουν ανώτερη σταθερότητα μετά από αποθήκευση και/ή έκθεση σε αυξημένες θερμοκρασίες. Οι GLP-2 συνθέσεις περιλαμβάνουν ένα GLP-2 πεπτίδιο ή ένα ανάλογο αυτού, ένα ρυθμιστικό διάλυμα φωσφορικών, L-ιστιδίνη, και μαννιτόλη.
CY20071100588T 1999-12-30 2007-05-04 Glp-2 σκευασματα CY1106558T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9930882.7A GB9930882D0 (en) 1999-12-30 1999-12-30 GLP-2 formulations
PCT/US2000/035512 WO2001049314A2 (en) 1999-12-30 2000-12-29 Glp-2 formulations

Publications (1)

Publication Number Publication Date
CY1106558T1 true CY1106558T1 (el) 2012-01-25

Family

ID=10867197

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100588T CY1106558T1 (el) 1999-12-30 2007-05-04 Glp-2 σκευασματα

Country Status (13)

Country Link
US (1) US7056886B2 (el)
EP (1) EP1246639B1 (el)
JP (3) JP5001498B2 (el)
AT (1) ATE353665T1 (el)
AU (1) AU782110B2 (el)
CA (1) CA2395814C (el)
CY (1) CY1106558T1 (el)
DE (1) DE60033437T2 (el)
DK (1) DK1246639T3 (el)
ES (1) ES2282161T3 (el)
GB (1) GB9930882D0 (el)
PT (1) PT1246639E (el)
WO (1) WO2001049314A2 (el)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
CA2485703A1 (en) 2002-05-24 2003-12-04 Fred W. Wagner Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
JP2005534647A (ja) 2002-06-07 2005-11-17 ダイアックス、コープ 失血の予防及び軽減
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7166576B2 (en) 2002-08-28 2007-01-23 Dyax Corp. Methods for preserving organs and tissues
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
WO2004105790A1 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
ES2375056T3 (es) * 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
JP5518282B2 (ja) * 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
AU2004288854B2 (en) * 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
CN104826116A (zh) * 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
WO2005067368A2 (en) 2003-11-21 2005-07-28 Nps Allelix Corp. Production of glucagon like peptide 2 and analogs
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7847061B2 (en) 2004-11-01 2010-12-07 Nps Pharmaceuticals, Inc. Treatment of short bowel syndrome patients with colon-in-continuity
JP5175103B2 (ja) * 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス 安定なペプチド製剤
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
PL1931350T5 (pl) 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Podanie inhibitorów dipeptydylo-peptydazy
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
EP2001500A4 (en) * 2006-03-10 2010-07-28 Dyax Corp FORMULATIONS FOR ECALLANTIDE
US7879805B2 (en) 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
RU2540922C2 (ru) 2008-10-30 2015-02-10 Ново Нордиск А/С Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
EP2490708B1 (en) * 2009-10-22 2013-03-27 Biodel Inc. Stabilized glucagon solutions
US9610329B2 (en) 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
CA2787360C (en) 2010-02-03 2019-03-05 Takeda Pharmaceutical Company Limited Pyrrol0[3,2-c]pyridinyl-4-benzamide compounds and their use as apoptosis signal-regulating kinase 1 inhibitors
US9782455B2 (en) 2010-08-30 2017-10-10 Nps Pharmaceuticals, Inc. Solid phase synthesis of h(Gly2)GLP-2
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
CN103635489B (zh) 2011-01-06 2016-04-13 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
JP6033280B2 (ja) * 2011-04-22 2016-11-30 ラジウス ヘルス，インコーポレイテッド ＰＴＨ、ＰＴＨｒＰ、および関連ペプチドの薬剤送達方法
CN104080441B (zh) 2011-11-30 2020-02-28 3M创新有限公司 包括肽治疗剂和氨基酸的微针装置、制备和使用其的方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014096150A1 (en) 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
CN106459210A (zh) 2014-03-27 2017-02-22 戴埃克斯有限公司 用于治疗糖尿病黄斑性水肿的组合物和方法
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN104146969A (zh) * 2014-07-31 2014-11-19 浙江美华鼎昌医药科技有限公司 注射用或输注用比伐卢定冻干粉针制剂的制备方法
EP4039253A1 (en) 2015-04-29 2022-08-10 Radius Pharmaceuticals, Inc. Methods of treating cancer
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017098627A1 (ja) * 2015-12-10 2017-06-15 株式会社メニコン ペプチド組成物
EA201891388A1 (ru) 2015-12-11 2018-11-30 Дайэкс Корп. Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
EP3296746A1 (en) * 2016-09-20 2018-03-21 Université de Bourgogne In vitro method for diagnosing at early stage intestinal ischemia
TWI591177B (zh) 2016-10-27 2017-07-11 中化合成生技股份有限公司 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
WO2018142363A1 (en) * 2017-02-06 2018-08-09 Orbicular Pharmaceutical Technologies Private Limited Ready to use compositions of glp-2 analogues through self-administrable devices
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
FR3079414B1 (fr) * 2018-03-27 2020-05-01 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3072875B1 (fr) * 2017-10-31 2020-11-06 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
EP3628682A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628683A1 (en) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
MX2021004331A (es) 2018-10-26 2021-05-27 Novo Nordisk As Composiciones estables de semaglutida y usos de las mismas.
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
KR20210144607A (ko) * 2020-05-22 2021-11-30 한미약품 주식회사 Glp-2의 지속형 결합체의 액상 제제
KR20230038187A (ko) 2020-06-09 2023-03-17 벡티브바이오 에이지 아프라글루타이드의 제조, 제형화 및 투여

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5652216A (en) * 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
JPH11510170A (ja) * 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP0906338B1 (en) 1996-04-12 2002-11-06 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
WO1998025955A2 (en) * 1996-12-13 1998-06-18 Allelix Biopharmaceuticals Inc. Cloned glucagon-like peptide-2 receptors
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations

Also Published As

Publication number Publication date
AU782110B2 (en) 2005-07-07
WO2001049314A3 (en) 2002-01-03
EP1246639B1 (en) 2007-02-14
JP2012116861A (ja) 2012-06-21
US7056886B2 (en) 2006-06-06
JP5001498B2 (ja) 2012-08-15
PT1246639E (pt) 2007-05-31
JP2014159463A (ja) 2014-09-04
EP1246639A2 (en) 2002-10-09
US20010027180A1 (en) 2001-10-04
AU2462601A (en) 2001-07-16
DE60033437T2 (de) 2007-11-29
DK1246639T3 (da) 2007-06-11
DE60033437D1 (de) 2007-03-29
GB9930882D0 (en) 2000-02-23
ATE353665T1 (de) 2007-03-15
JP5604463B2 (ja) 2014-10-08
CA2395814A1 (en) 2001-07-12
WO2001049314A2 (en) 2001-07-12
JP2003519195A (ja) 2003-06-17
JP5934739B2 (ja) 2016-06-15
CA2395814C (en) 2011-09-20
ES2282161T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
CY1106558T1 (el) Glp-2 σκευασματα
NO20024891D0 (no) Farmasöytiske sammensetninger
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
CY1113318T1 (el) Ελευθερα απο ψευδαργυρο και φτωχα σε ψευδαργυρο σκευασματα ινσουλινης με βελτιωμενη σταθεροτητα
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
CY1108547T1 (el) Αναλογα σωματοστατινης
CY1105538T1 (el) Ιατρικη μορφοποιηση αερολυματος
DK1003504T3 (da) Indolderivater og deres anvendelse som PCP-1-antagonister
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
BR0209434A (pt) Peptìdeos antimicrobianos e composições
EA199800752A1 (ru) Пентафторбензолсульфонамиды и их аналоги
CY1106049T1 (el) Παραγωγα ινδολης
CY1105010T1 (el) Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
CY1106633T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν χαλκο, σαλικυλικο οξυ και βιταμινη c
ATE331037T1 (de) Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff
DK0896615T3 (da) Peptid fra opløselig form af acetylcholinesterase, der er aktivt som calcium-kanal-modulator
NO20073914L (no) Biologisk aktive peptider
ATE440960T1 (de) T-helferzellen-epitope
CY1106967T1 (el) Παραγωγα πεπτιδιων χαμηλου μοριακου βαρους ως αναστολεις της αλληλεπιδρασης λαμινινης/εντακτινης
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
BR9811821A (pt) 2-acilaminopropanaminas como antagonistas de receptores de taquicinina